A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy-Reference-Cited by-同舟云学术

A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy

Published:2020-06-12 Issue:9 Volume:99 Page:2133-2139
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Fuji Shigeo^ORCID,Tada Yuma,Nozaki Kenji,Saito Hideaki,Ozawa Takayuki,Kida Toru,Kosugi Satoru,Sugahara Hiroyuki,Ikeda Hirokazu,Hashimoto Koji,Karasuno Takahiro,Ueda Shuji,Ishikawa Jun,Shibayama Hirohiko

Funder

Health Promotion Administration, Ministry of Health and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04126-y.pdf

Reference25 articles.

1. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122(6):981–987. https://doi.org/10.1182/blood-2013-03-491514

2. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516–2522. https://doi.org/10.1200/JCO.2014.59.7534

3. Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW (2019) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol 184(4):660–663. https://doi.org/10.1111/bjh.15149

4. Rivas-Delgado A, Magnano L, Moreno-Velazquez M, Garcia O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, Gonzalez-Farre B, Martinez A, Balague O, Delgado J, Villamor N, Gine E, Campo E, Sancho-Cia JM, Lopez-Guillermo A (2019) Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 184(5):753–759. https://doi.org/10.1111/bjh.15708

5. Welaya K, Casulo C (2019) Follicular lymphoma: redefining prognosis, current treatment options, and unmet needs. Hematol Oncol Clin North Am 33(4):627–638. https://doi.org/10.1016/j.hoc.2019.03.003

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse large B-cell lymphoma and follicular lymphoma: problem state in Russia;Journal of Modern Oncology;2024-07-03

2. Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China;Frontiers in Oncology;2023-10-24

3. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis;BMC Cancer;2023-01-23

4. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial;International Journal of Hematology;2022-11-21

5. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study;Haematologica;2022-10-20